Linder the Panerunck Reduction Art of 1995, no necessary are received in

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Arger		nta, et al.		
Art Unit		3733		
Examiner Name PHIL		DGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

					U.S.	PATENTS			Remove		
			Kind Code <sup>1</sup>	Issue Date Name of Patentee of Applicant			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wis	h to a	l dd additional U.S. Patei	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		Publication Name of Patentee or Applicant Releva		s,Columns,Lines where ant Passages or Releves Appear				
	1										
If you wis	h to a	dd additional U.S. Publi						d button	=		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	Ι.,
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10647068		
	Filing Date		2003-08-22		
	First Named Inventor	Argen	nta, et al.		
	Art Unit		3733		
	Examiner Name PHILO		DGENE, PEDRO		
			0404 D02077UC4		

1	Opposition to EP 0,620,720 - Communication of Opponent Hartman (Opening Brief) (11 pp.) dated (December 16, 1998). EPOPWH1-01		
2	Opposition to EP 0,520,720 - Communication of Opponent Mondomed N.V. (5 pp.) (dated December 17, 1998). EPOPWH1-02		
3	Opposition to EP 0,520,720 - Communication of Patentile (Response Binef) with Exhibits, (37pp.) (dated October 15, 1999), EPOPWH-03		
4	Opposition to EP 0,620,720 - Communication of Opponent Hartman (Brief in Reply to Patenties's Brief) (8 sheets with 8 sheets of English translation) (dated March 8, 2000). EPOPWH1-04	×	
5	Opposition to EP 0,620,720 - Communication of Patentiee (12 pp. of briefl), with Exhibits (3 pp.) (dated September 22, 2000), EPOPWH-05		
6	Opposition to EP 0,620,720 - Communication of Opponent Mondomed (13 pp.) (dated May 3, 2001). EPOPWH1-06		
7	Opposition to EP 0,820,720 - Communication of Opponent Mondomed (2 pp.) (dated August 8, 2001). EPOPWH1-07		
8	Opposition to EP 0,620,720 - Preliminary Opinion of Opposition Division (5 pp.), Summons to Oral Proceedings Pursuant to Rule 71(1) EPC, and Communication of EPO (Form 2505) (6 pp.) (dated August 12, 2003) EPOPWH1-08		
9	Opposition to EP 0,520,720 - Third-Party Communication (3 pp.) (dated August 14, 2003). EPOPWH1-09		
10	Opposition to EP 0,620,720 - Communication of Patenties, with exhibits, (11 pp. of letter) (with 15 sheets of enclosures) (dated November 9, 2003), EPOPWH1-10		
11	Opposition to EP 0,620,720 - Third-Party Communication (2 pp.) (dated November 12, 2003). EPOPWH1-11		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Argent		nta, et al.		
Art Unit		3733		
Examiner Name	PHILO	DGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

12	Opposition to EP 0,620,720 - Communication of Patentee (3 pp.) (dated November 25, 2003). EPOPWH1-12	
13	Opposition to EP 0.620,720 - Communication of Opponent Hartman, (2 pp.), (dated July 19, 2004). EPOPWH1-14	
14	Opposition to EP 0.620,720 - Third-Party Communication (5 sheets) (dated February 15, 2005). EPOPWH1-19	
15	Opposition to EP 0,620,720 - Summons to attend onal proceedings pursuant to Rule 71(1) EPC, Annex to communication, (9 sheets) both dated (February 13, 2002) and Communication from Opponent Mondomed N.V. (2 sheets) (dated February 15, 2002). EPOPWH1-21	
16	Opposition to EP 0,620,720 - Minutes of the Oral Proceedings, Documents for the Maintenance of the Patent as Amended, Annex to the Communication (30 sheets) (dated December 30, 2003). EPOPWH1-22	
17	Opposition to EP 0,620,720 - Communication of Notices of Opposition (Rule 57(1) EPC) dated (February 8, 1999) (1 street), Notice of Opposition by Manchand KV., (4 sheets) and 6 sheets of Facts and Arguments presented in support of opposition (select July 1, 1998), EPCPWH1-23	
18	Opposition to EP 0,620,720 - Notice of Opposition by Paul Hartmann A.G., (6 sheets) (dated December 16, 1986). EPOPWH1-24	
19	Opposition to EP Patent 0,620,720 - New European Palent Specification EP 062072082 (published November 2, 2006). EPOPWH-25	
20	Opposition to EP 0,620,720 - Letter to European Patent Office regarding Observations by a third party pursuant to Art 115 EPC, and attachment, (4 sheets) (dasted March 6, 2006). EPOPWH1-26	
21	Opposition to EP 0,688,189 - Interlocularly decision in opposition proceedings with grounds for the decision and annexes, (14 sheets) (dated February 17, 2003). EPOPWH2-06	
22	Opposition to EP 0,688,189 - Letter relating to appeal procedure and enciosures, (15 sheets) (dated June 27, 2003). EPOPWH2-08	

	Application Number		10647068	
	Filing Date		2003-08-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Argenta, et al.		nta, et al.	
( Not for submission under 37 CFR 1.99)	Art Unit		3733	
(NOCIOI SUBINISSION UNDER 37 OF K 1.33)	Examiner Name PHILOGENE, PEDRO		OGENE, PEDRO	
	Attorney Docket Numb	er.	0101-P02977US1	

If you wish to add add	ditional non-patent literature document citation information p	lease click the Add I	outton Add		
	EXAMINER SIGNATURE				
Examiner Signature		Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw lin					

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Patent Documents at swent/LEPTO.GOV or MPEP 901.94. Enter office that issued the document, by the hor-left own (WIPO Standard ST3.). For Legareses patent for comment, he end calculated on the year of the register of the Emperor many precise the serial remove of the patent document. If kind of document by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if Empirish languages the residence is a standard.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Argen		ta, et al.		
Art Unit		3733		
Examiner Name PHILI		OGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

#### CERTIFICATION STATEMENT

Please see 37 C	FR 1.97 and	1.98 to make the	appropriate selection(s):
-----------------	-------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Na Na-

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haurr/	Date (YYYY-MM-DD)	2007-04-23
Name - (Dalas)	Minin Union	Designation Number	40 400

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.